HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • HC-7366
    • HC-5404
    • Odetiglucan
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • HC-7366
    • HC-5404
    • Odetiglucan
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers

Publication Type: Publication

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent

Posts navigation

Newer posts
HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • HC-7366
    • HC-5404
    • Odetiglucan
  • Pipeline
  • News & Publications
  • Contact
  • Careers
Linked In

© 2025 Hibercell Inc |
Privacy Policy |
Terms & Conditions |
Expanded Access